SCHEMBL31311234

SCHEMBL31311234

O=C(O)c1scnc1-c1ccc(F)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMO O15229 4/20 0.50
RORB Q92753 4/20 0.48
RPA1 P27694 1/20 0.46
RORC P51449 2/20 0.44
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
ABL1 P00519 1/20 0.42
CASP1 P29466 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
MARS1 P56192 1/20 0.39
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
CSNK2A1 P68400 1/20 0.39
MDM2 Q00987 1/20 0.39
EPHB4 P54760 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31311178 0.87 CASP1 (0.48) KMORORBRORCADORA2AADORA1
SCHEMBL31311304 0.84 RORB (0.44) KMORORBRPA1RORCADORA2A
SCHEMBL31311314 0.84 ABL1 (0.47) KMORORBRORCADORA2AADORA1
SCHEMBL24508647 0.79 KDM4E (0.46) RPA1KDM4EPKM
SCHEMBL13398825 0.77 KDM4E (0.56) KMORPA1ABL1CASP1NPC1
SCHEMBL24508717 0.77 ALDH1A2 (0.50) KMORORBRORCADORA2AKDM4E
SCHEMBL24508613 0.75 KDM4E (0.46) KMORORBRORCNPC1RAB9A
SCHEMBL13494039 0.75 KMO (0.47) KMORPA1ADORA2AADORA1ABL1
SCHEMBL6484895 0.74 EGFR (0.45) KMONPC1RAB9ACSNK2A1
SCHEMBL4373610 0.74 RORB (0.46) RORBCASP1NPC1RAB9AMARS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731206-A2 COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES Veralox Therapeutics Inc. (US) 2026-04-29 EP disclosed
WO-2024264032-A2 COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES VERALOX THERAPEUTICS INC. (US) 2024-12-26 WO disclosed